Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Metastatic colorectal cancer Clinical criteria: Treatment Phase: Initial PBS-subsidised treatment Patient must have/had a WHO performance status of 1 or less, prior to initiation of treatment with this drug for this condition, AND Patient must not have previously received PBS-subsidised treatment with this drug for this PBS indication; OR Patient must be each of: (i) currently receiving non-PBS-subsidised supply for this drug for this PBS indication, (ii) untreated with this drug at the time that non-PBS-subsidised supply was commenced, (iii) free of disease progression since commencing non-PBS-subsidised supply, AND Patient must have been previously treated with or not considered a candidate for treatment with fluoropyrimidine, oxaliplatin, irinotecan-based chemotherapies, an anti-vascular endothelial growth factor (anti-VEGF) agent and an anti-epidermal growth factor receptor (anti-EGFR) agent for this condition, AND The treatment must be the sole PBS-subsidised therapy for this condition. The patient's WHO performance status must be documented in the patient's medical records at the time the treatment is initiated.
“Fruquintinib is a small molecule tyrosine kinase inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2, and -3 (with IC 50 values of 33, 35, and 0.5 nM, respectively), with antitumor effects resulting from suppression of tumour angiogenesis.”
“The fruquintinib mean (SD) elimination half-life is approximately 42 (11) hours and the apparent clearance is 14.8 (4.4) mL/min.”
Curated subset. The full adverse-effect list is in the TGA Product Information; click any citation above to open it.
“CYP3A4 was the main CYP enzyme isoform involved, with minor contributions from CYP2C8, CYP2C9 and CYP2C19. Fruquintinib is not an inhibitor of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 and CYP3A, or an inducer of CYP1A2, CYP2B6, CYP3A.”